Search

The diagnostic performance of neurofilament light chain

A systematic review and meta-analysis.



Check out our latest publication reviewing the diagnostic performance of neurofilament light chain (NfL) in CSF and blood in the context of Alzheimer's disease (AD), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS) compared with controls (i.e., cognitively unimpaired, mild cognitive impairment, or disease mimics).


Forgrave LM, Ma M, Best JR, DeMarco ML. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2019;11:730-743.


CONCLUSIONS

Comparable performance of CSF and blood NfL in many groups demonstrates the promise of NfL as a noninvasive biomarker of neurodegeneration; however, its utility in clinically meaningful scenarios requires greater scrutiny. Toward clinical implementation, a more comprehensive understanding of NfL concentrations in disease subtypes with overlapping phenotypes and at defined stages of disease, and the development of a harmonization program, are warranted.



9 views
Address
 

St. Paul's Hospital

Dept of Pathology & Laboratory Medicine

1081 Burrard St, Vancouver Canada, V6Z 1Y6

Connect

Web: www.DeMarcoLab.ca

Email: mdmrco [at] mail.ubc.ca

© 2020 M.L.DeMarco